持久性细胞表型导致PDAC中新辅助化疗后患者的治疗结果不佳
Xu Zhou1,2, Jingyu An1,2, Roma Kurilov3
1Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Nature cancer
|September 7, 2023
概括
在胰腺癌中,新辅助性化疗反应与特定的细胞标记物有关. 识别这些GATA6和KRT17表达细胞可能会指导未来的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 新辅助化疗改善了胰腺管腺癌的存活率,但由于患者的反应不同,它面临着挑战.
- 了解治疗影响对于优化患者的治疗结果至关重要.
研究的目的:
- 确定新辅助化疗对胰腺管道腺癌的影响.
- 识别与治疗反应和生存相关的细胞表型.
主要方法:
- 在患者样本上进行RNA测序和多重免疫光学 (化疗前和后新辅助化疗).
- 转录组分析和高分辨率组织映射.
- 来自患者样本的器官模型.
主要成果:
- 在化疗后,GATA6 (古典),KRT17 (基底类) 和细胞染色体P450 3A (CYP3A) 联合表达的细胞得到了丰富.
- 持久的GATA6和KRT17表达与mFOLFIRINOX (mFFX) 后的生存率差相关,但不是gemcitabine (GEM).
- CYP3A的表达预测了化疗反应,其途径代谢了氨酸 (mFFX的组成部分).
结论:
- 在剩余的胰腺癌中确定了表达CYP3A的耐药细胞表型.
- 这些发现可能有助于选择辅助治疗.
- GATA6和KRT17的表达水平可以预测对特定化疗方案的治疗反应.
更多相关视频
12:41Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
4.9K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
相关概念视频
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
